📊 KOD Key Takeaways
Is KOD a Good Investment? Thesis Analysis
Kodiak Sciences is a cash-burning biotech firm with zero reported revenue, indicating either failed commercialization or pre-revenue status. Despite a solid cash position of $209.9M, annual operating losses of $234.4M and negative free cash flow of $136.5M provide only ~18 months of runway, forcing imminent capital raises that will dilute shareholders. Negative ROE of -146% and deteriorating operating fundamentals signal fundamental business failure without dramatic turnaround evidence.
Why Buy KOD? Key Strengths
- Strong absolute cash position of $209.9M provides near-term liquidity buffer
- Excellent liquidity ratios (4.72x current ratio) indicate ability to meet short-term obligations
- Zero debt eliminates financial leverage risk and creditor obligations
KOD Investment Risks to Consider
- Complete absence of commercial revenue indicates product approval or market acceptance failure
- Extreme cash burn rate of $136M annually with only ~18 months of runway remaining
- Massive net losses of $230M and operating losses of $234.4M with worsening year-over-year trends
- Inevitable dilutive capital raises required within 12-18 months to sustain operations
- Negative ROE (-146%) and ROA (-65%) reflect severe operational inefficiency
Key Metrics to Watch
- Quarterly revenue growth and product commercialization announcements
- Operating cash flow burn rate and estimated cash runway
- Debt/equity ratio and upcoming capital raise announcements
KOD Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.72x current ratio provides a solid financial cushion.
KOD Profitability Ratios
KOD vs Healthcare Sector
How Kodiak Sciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KOD Overvalued or Undervalued?
Based on fundamental analysis, Kodiak Sciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KOD Balance Sheet & Liquidity
KOD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Kodiak Sciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.97 indicates the company is currently unprofitable.
KOD Growth Metrics (YoY)
KOD Capital Allocation
KOD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Kodiak Sciences Inc. (CIK: 0001468748)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KOD
What is the AI rating for KOD?
Kodiak Sciences Inc. (KOD) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KOD's key strengths?
Claude: Strong absolute cash position of $209.9M provides near-term liquidity buffer. Excellent liquidity ratios (4.72x current ratio) indicate ability to meet short-term obligations.
What are the risks of investing in KOD?
Claude: Complete absence of commercial revenue indicates product approval or market acceptance failure. Extreme cash burn rate of $136M annually with only ~18 months of runway remaining.
What is KOD's revenue and growth?
Kodiak Sciences Inc. reported revenue of N/A.
Does KOD pay dividends?
Kodiak Sciences Inc. does not currently pay dividends.
Where can I find KOD SEC filings?
Official SEC filings for Kodiak Sciences Inc. (CIK: 0001468748) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KOD's EPS?
Kodiak Sciences Inc. has a diluted EPS of $-4.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KOD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kodiak Sciences Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KOD stock overvalued or undervalued?
Valuation metrics for KOD: ROE of -146.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KOD stock in 2026?
Our dual AI analysis gives Kodiak Sciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KOD's free cash flow?
Kodiak Sciences Inc.'s operating cash flow is $-136.0M, with capital expenditures of $506.0K.
How does KOD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -146.1% (avg: 15%), current ratio 4.72 (avg: 2).